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Background:  Continuous  surveillance  for  genetic  changes  in circulating  inﬂuenza  viruses is  needed  to
guide  inﬂuenza  prevention  and control.
Objectives:  To  compare  intra-seasonal  inﬂuenza  genetic  diversity  of  hemagglutinin  in inﬂuenza  A strains
isolated  from  inﬂuenza  hospital  admissions  collected  at two  distinct  sites  during  the same  season.
Study  design:  Comparative  phylogenetic  analysis  of  full-length  hemagglutinin  genes  from  77 isolated
inﬂuenza  A  viruses  from  the St. Petersburg,  Russian  Federation  and  Valencia,  Spain  sites  of  the  Global
Inﬂuenza  Hospital  Surveillance  Network  (GIHSN)  during  the  2013/14  season.
Results: We  found  signiﬁcant  variability  in  A(H3N2)  and A(H1N1)pdm09  viruses  between  the two  sites,
with  nucleotide  variation  at  antigenic  positions  much  lower  for A(H1N1)pdm09  than  for A(H3N2)  viruses.
For  A(H1N1)pdm09,  antigenic  sites  differed  by  three  to four  amino  acids  from  the vaccine  strain,  two  of
them  common  to all tested  isolates.  For  A(H3N2)  viruses,  antigenic  sites  differed  by six  to  nine  amino
acids  from  the vaccine  strain,  four of  them  common  to all tested  isolates.  A ﬁfth amino  acid substitution
in  the antigenic  sites  of  A(H3N2)  deﬁned  a new clade, 3C.2.  For  both  inﬂuenza  A  subtypes,  pairwise  amino
acid  distances  between  circulating  viruses  and  vaccine  strains  were  signiﬁcantly  higher  at  antigenic  than
at non-antigenic  sites.  Whereas  A(H1N1)pdm09  viruses  clustered  with  clade  6B and  94% of  A(H3N2)
with  clade  3C.3,  at both  study  sites  A(H3N2)  clade  3C.2  viruses  emerged  towards  the  end  of the  season,
showing  greater  pairwise  amino  acid  distances  from  the  vaccine  strain  compared  to  the  predominant
clade  3C.3.
Conclusions:  Inﬂuenza  A  antige
clade  3C.2  viruses  were  charac
at the  antigenic  sites.
©  2016  The  Autho
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. Background
As a consequence of error-prone replication of the viral RNA
enome and host immune pressure, the antibody-binding sites
f inﬂuenza A hemagglutinins (HAs) continuously accumulate
utations [1,2]. The emergence of variants escaping natural
r vaccine-induced immune responses (antigenic drift) leads to
nnual inﬂuenza epidemics in humans [3,4], a major cause of mor-
idity and mortality and a signiﬁcant economic burden on health
ervices [5]. Continuous surveillance of circulating inﬂuenza strains
s needed to identify new mutations in HA that can escape from host
ntibody responses [6–8] and thereby guide inﬂuenza prevention
nd control [9].
. Objectives
Here, we compared the intra-seasonal inﬂuenza HA genetic
iversity and differences from the vaccine strains in the A(H3N2)
nd A(H1N1)pdm09 inﬂuenza viruses collected at two sites
Valencia, Spain and St. Petersburg, Russian Federation) of the
lobal Inﬂuenza Hospital Surveillance Network (GIHSN) during
he 2013/14 Northern Hemisphere inﬂuenza season. The GIHSN
ocuses exclusively on severe cases of respiratory infection requir-
ng hospitalization and conducts a prospective, active surveillance,
ospital-based epidemiological study over consecutive seasons
10].
. Study design
.1. Samples
Clinical samples for the study were collected from a prospec-
ive surveillance scheme conducted at St. Petersburg, Russian
ederation and Valencia, Spain during the 2013/14 Northern Hemi-
phere inﬂuenza season. Study details and inclusion criteria are
escribed elsewhere [10]. A nasopharyngeal and a pharyngeal swab
ere obtained from each patient using ﬂocked swabs, submerged
n transport media, and frozen at −20 ◦C until shipment to the
eference virology laboratory for analysis (Virology Laboratory,
ISABIO-Public Health, Valencia, Spain and World Health Organi-
ation National Inﬂuenza Centre (RII NIC), St. Petersburg, Russian
ederation).
.2. Molecular diagnosis, typing, and sequencing of inﬂuenza
iruses
Molecular diagnosis, typing, and sequencing of inﬂuenza viruses
omplied with the World Health Organization recommendations
11]. In Valencia, total nucleic acid was extracted using an auto-
ated method (Nuclisens Easy-Mag, bioMérieux, Lyon, France).
nﬂuenza A and B viruses were screened by multiplex real-time
everse-transcription polymerase chain reaction (RT-PCR) in a
ightcycler 480II (Roche Applied Science, Penzberg, Germany) as
escribed [12,13]. A typing real-time RT-PCR assay was performed
ollowing the World Health Organization protocol [11] for all
nﬂuenza A-positive samples.
In St. Petersburg, viral RNA was extracted using a RIBO-
rep kit (InterLabService, Russian Federation) or an RNeasy Mini
it (Qiagen, Hilden, Germany). RT-PCR for inﬂuenza A and B
iruses was performed using AmpliSens Inﬂuenza virus A/B-FL,
mpliSens Inﬂuenza virus H1/swine-FL, and AmpliSens Inﬂuenza
irus A type-FL kits (InterLabService, Russian Federation) with
everse transcription using an AmpliSens Reverta-L kit (InterLab-
ervice, Russian Federation) or an AgPath-IDTM One-Step RT-PCR
it (Ambion, USA) with US Centers for Disease Control and Pre-linical Virology 84 (2016) 32–38 33
vention primers and probes to determine the lineage (Yamagata or
Victoria) for inﬂuenza B viruses.
HA nucleotide sequencing was performed on every fourth sam-
ple positive for inﬂuenza A (Valencia) or on convenience samples
(cycle threshold values <25) taken at the beginning, middle, and end
of the inﬂuenza season (St. Petersburg). At both sites, the complete
HA gene (HA1/HA2 regions) was  ampliﬁed by long-range RT-PCR
and sequenced by standard Sanger chemistry using gene-speciﬁc
primers for the corresponding virus subtype [11].
3.3. Inﬂuenza variability and phylogenetic analysis
3.3.1. Sequence data
Nucleotide alignments were obtained using the ClustalW algo-
rithm integrated in BioEdit ver.7.2.5 (Ibis Biosciences, Carlsbad,
CA, USA) [14], including reference sequences (deﬁning known
phylogenetic clades) from the Global Initiative on Sharing Avian
Inﬂuenza Data (GISAID) database (Annex 1 of Supplementary
information). Maximum-likelihood phylogenetic trees were recon-
structed using the whole HA gene sequence with the online PhyML
platform (http://www.atcg-montpellier.fr/phyml). The best-ﬁtting
nucleotide substitution model (general time-reversible + gamma
distribution among the sites) was  estimated using Modeltest [15]
integrated in MEGA 5.0 [16]. Branch reliability was  evaluated by
an approximate likelihood-ratio test (Chi-squared statistic-based)
with an interior branch cut-off value of 0.9. The trees were rooted
on the 2013/14 recommended vaccine strains A/California/7/2009
for A(H1N1)pdm09 or A/Texas/50/2012 for A(H3N2) viruses [17].
3.3.2. Genetic complexity and diversity
Genetic polymorphism and diversity [18] between Valencia and
St. Petersburg viruses were estimated with DnaSP version 5 [19]. All
parameters were calculated for the whole HA gene region and for
the HA1 and HA2 subunits separately, as well as for non-antigenic
sites only or for antigenic sites only (A–E of the H3 scheme and
their equivalents Sa, Sb, Ca1, Ca2 and Cb for H1; reviewed in [20]).
Nucleotide diversity (haplotypes) was calculated either consider-
ing only antigenic sites (aHap) or considering the full-length HA
gene (Hap), to estimate the fraction of individual viral isolates for
each haplotype. Pairwise amino acid distances between individual
viral isolates and the corresponding vaccine strain were calculated
using the p-distance model implemented in MEGA 6 [21]. Non-
parametric Kruskal–Wallis tests were used to compare pairwise
amino acid distances from vaccine strains. All statistical analyses
were performed using Stata version 12 (StataCorp, College Station,
TX).
4. Results
4.1. Samples
Samples were collected from early December, 2013 to mid-
March, 2014, and half were collected during the seasonal peak of
activity (January, 2014 for A(H1N1)pdm09 and February, 2014 for
A(H3N2) viruses). Complete HA gene sequences could be deter-
mined for 34 A(H1N1)pdm09 and 26 A(H3N2) isolates collected in
Valencia and for eight A(H1N1)pdm09 and nine A(H3N2) isolates
collected in St. Petersburg. For A(H1N1)pdm09-positive samples,
patient ages ranged from 0.1 to 83 years, with a median of 62 years
for Valencia and 5 years for St. Petersburg. For A(H3N2)-positive
samples, patient ages ranged from 2 to 94 years, with a median of
73 years for Valencia and 18 years for St. Petersburg.
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Table  1
Genetic polymorphism estimates for HA domains in each viral population for inﬂuenza A(H1N1)pdm09 and A(H3N2) viruses.
Subtype Variable HA total Antigenic sites
Valencia St. Petersburg Valencia St. Petersburg
A(H1N1)pdm09 Total number of sites 1647 150
Number of sequences 34 8 34 8
H  21 6 6 2
Hd  0.911 0.929 0.41 0.25
S  65 20 4 1
Eta  () 67 20 5 1
Singleton variable sites 46 12 3 1
k  6.752 6.893 0.533 0.25
Pi() 0.0041  0.00419 0.00355 0.00167
Theta  () per site 0.00965 0.00468 0.00815 0.00257
Ss  45 15 3 0
s  0.01248 0.01407 0.01186 0
syn  per site NA 0.01541 0.02086 0
Sa  22 5 2 1
a  0.00163 0.00126 0.00101 0.00219
a  per site NA 0.00152 0.00426 0.00336
A(H3N2) Total number of sites 1650 393
Number of sequences 26 9 26 9
H  21 7 13 6
Hd  0.966 0.917 0.788 0.833
S  61 42 17 19
Eta  () 61 42 17 19
Singleton variable sites 45 32 13 14
k  6.991 12.111 2.123 5.556
Pi() 0.00424 0.00734 0.00540 0.01414
Theta  () per site 0.00969 0.00937 0.01134 0.01779
Ss  39 24 12 8
s  0.01255 0.01967 0.0218 0.02934
syn  per site 0.02808 0.02425 0.03945 0.03532
Sa  22 18 5 11
a  0.00188 0.00385 0.00123 0.01005
a  per site 0.00448 0.00515 0.00418 0.01307
Abbreviations: H, number of haplotypes; Hd, haplotype gene diversity; S, total number of segregating (polymorphic) sites; Eta (), total number of mutations; k, average
number  of nucleotide differences; NA, not applicable; Pi (), nucleotide diversity (average number of nucleotide differences per site between two  sequences); theta (),
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ynonymous sites; a, heterozygosis per site at non-synonymous loci.
.2. Overall variability of inﬂuenza viruses between study sites
Across the full HA gene, A(H1N1)pdm09 and A(H3N2) HA viral
equences from Valencia showed more nucleotide polymorphic
ites than those from St. Petersburg (Table 1). No single nucleotide
ite differentiated all isolates from St. Petersburg from all isolates
rom Valencia, or the converse (data not shown). A(H3N2) viruses
hared more mutations across study sites than A(H1N1)pdm09
iruses. Nucleotide diversity was higher for A(H3N2) isolates
rom St. Petersburg than for those from Valencia. At both loca-
ions, estimated nucleotide diversity for A(H3N2) viruses was
igher in antigenic sites than in other regions of HA, whereas for
(H1N1)pdm09, diversity was lower in antigenic sites than in other
A regions.
.3. Phylogenetic analysis and differences in antigenic sites
.3.1. A(H1N1)pdm09 viruses
Inﬂuenza A(H1N1)pdm09 viruses from Valencia and St. Peters-
urg clustered in monophyletic subgroup 6B, represented by
/South Africa/3626/2013 (Fig. 1a). Up to 93% (39/42) of the viruses
elonged to the same antigenic-site amino acid haplotype (aHap1,
ig. 2a) deﬁned by substitutions K163Q (Sa), S185T (Sb), and
203T (Ca1) relative to the vaccine strain A/California/7/2009. One
irus (St. Petersburg, February 2014) had a substitution K163R
n antigenic site Sa. Two remaining isolates (Valencia, December
013–January 2014) had a fourth substitution at S74 in antigenic
ite Cb.bserved S value; Ss, number of polymorphic synonymous changes; s, nucleotide
ber of polymorphic non-synonymous changes; a, nucleotide diversity at non-
Analysis of non-antigenic sites revealed seven additional muta-
tions: P83S, D97N, A256T, and K283E in HA1; and E374K, S451N,
and E499K in HA2 (Fig. 2b). Only one isolate (Valencia, Jan. 2014)
contained the D97S substitution also present in the 2012/13
viruses. In addition, 38/42 (90%) of all viruses had the I321V
mutation and 22/42 (52%) carried the A315V mutation (HA1).
The remaining substitutions (n = 21) were mostly singletons in a
few positions of HA1 or scattered across HA2. Overall, variants
outside the antigenic sites divided antigenic aHap1 into 11 sub-
haplotypes, but only two, Hap3 and Hap6 (differing at residue
A315V), accounted for 64% of all viruses (Fig. 2b). Viruses from
St. Petersburg had, on average, the same number of amino acid
changes as those from Valencia (12.3 vs. 12.5 for the full-length
HA, 9.0 vs. 8.9 for HA1, and 3.3 vs. 3.6 for HA2).
Overall, haplotypes were population-speciﬁc (P = 0.008 by Chi-
squared test) and only Hap3 was shared at both sites (3/8 [37%]
from St. Petersburg, 5/34 [15%] from Valencia). The peak of hap-
lotype diversity occurred in February in St. Petersburg and in late
January 2014 in Valencia (Fig. 3a and b). Hap3, common to both
study sites, was  detected from mid-late January 2014 until the end
of the season in both locations, whereas the Valencia-speciﬁc Hap6,
present in 19/34 (56%) viruses, circulated between December 2013
and March 2014. Based on the sampling date, we deduced that
intra-seasonal antigenic sites haplotypes co-circulated contempo-
raneously in each study site and did not displace one another over
the course of the season (data not shown).
F.X. López-Labrador et al. / Journal of Clinical Virology 84 (2016) 32–38 35
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alencia and St. Petersburg sites during the 2013/14 season.
.3.2. A(H3N2) viruses
Most of the A(H3N2) viruses (94%; 33/35) belonged to clade 3C.3
A/Samara/73/2013-like) and only a few (6%; 2/35) to clade 3C.2
A/Hong Kong/146/2013-like) (Fig. 1b). Each clade had a median of
 (range, 6–9) substitutions at antigenic sites relative to the vac-
ine reference strain A/Texas/50/2012. Both clades had the same
umber of amino acid substitutions relative to the vaccine strain
nd diverged at the clade-deﬁning residue N128 (site B), resulting in
he loss of a potential glycosylation site (substitution N128T at clade
C.2 and N128A at clade 3C.3). In addition to N128A/T, for all iso-
ates, differences between circulating and vaccine viruses included
145S (site A), V186G (site B), P198S (site B), and F219S (site D)
Fig. 4a). The following additional substitutions were present in
ntigenic sites: 69% (24/35) of viruses from clade 3C.3 carried the
122D substitution (site A), 91% (32/35) carried A142G (site A), and
9% (31/35) carried L157S (site B). Seven additional single substi- HA gene from inﬂuenza A(H1N1)pdm09 and A(H3N2) isolates collected from the
tutions scattered throughout antigenic sites A–E were unique to
clade 3C.3 and ﬁve were unique to clade 3C.2 (Fig. 4).
Consistent with substantial genetic diversity, clade 3C.3 had 13
aHaps (Fig. 4a), which were site-speciﬁc (P = 0.007 by Chi-squared
test). Overall, ﬁve dominant and three high-frequency substitutions
were present in the antigenic sites A, B and D, whereas singleton
substitutions (n = 12) were present mostly in sites C and E. Over
the whole season, aHap6 was  present in 54% (19/35) of all viruses
(Fig. 3c), 69% (18/26) of viruses from Valencia, and 11% (1/9) of
viruses from St. Petersburg (Fig. 4a). In St. Petersburg, 44% (4/9) of
the isolates had the St. Petersburg-speciﬁc aHap3 (Fig. 4a), which
circulated during the peak of the inﬂuenza season (Fig. 3c) and
differed from aHap6 at two residues within antigenic sites A and
E. The remaining haplotypes were collected throughout the sea-
son, except for clade 3C.2 aHap9 from Valencia and aHap4 from St.
Petersburg, which were collected towards the end of the season
(mid- to late March). Overall, intra-seasonal haplotypes circulated
36 F.X. López-Labrador et al. / Journal of Clinical Virology 84 (2016) 32–38
Fig. 2. Amino acid substitutions in the antigenic sites (a) and the full-length HA gene (b) for inﬂuenza A(H1N1)pdm09. Sites are numbered according the previously published
sequences for the vaccine and reference strains. Dots indicate amino acids identical to the reference sequence. Abbreviations: N, number of viruses collected; StP, St. Petersburg;
pw/dist, pairwise distance; V(n/T), number of vaccinated patients in the group/total number of patients in the group; VLC, Valencia. *Pairwise amino acid distances between
vaccine and each patient’s virus were calculated by using the p-distance model implemented in MEGA6.
F ologic
d
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t
t
aig. 3. Distribution of haplotypes for antigenic sites and full-length HA by epidemi
uring  the 2013/14 season.
oncurrently and did not displace one another over the course of
he season (Fig. 3c).
Additional amino acid changes at non-antigenic sites (n = 12;
wo of them at frequencies of 50% or higher) divided antigenic site
Hap6 into several sub-haplotypes (Fig. 4b). Only one of the sub-al week for A(H1N1) pdm09 and A(H3N2) viruses from Valencia and St. Petersburg
haplotypes, Hap6, (late December, 2013—early March, 2014) was
found at a high frequency (50%) in Valencia (Fig. 3d), bearing all of
the substitutions of aHap6 plus the two common mutations V529I
(66%) and V347M (94%) in the HA2 region. Singleton mutations
scattered across HA1 and HA2 non-antigenic sites accounted for
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equences for the vaccine and reference strains. Dots indicate amino acids identi
airwise distance; StP, St. Petersburg; V(n/T), number of vaccinated patients in the g
etween vaccine and each patient’s virus were calculated by using the p-distance m
ost of the additional variability. The peak of amino acid changes
ccurred in late January, 2014 in Valencia and mid-February, 2014
n St. Petersburg. During these peaks, only four full-length HA
aplotypes co-circulated in Valencia and three co-circulated in St.
etersburg (Fig. 3d).
.4. Pairwise amino acid distances between circulating viruses
nd vaccine strains
The median pairwise amino acid distances between the vaccine
nd A(H1N1)pdm09 circulating viruses was 0.06 (5th to 95th per-
entile range, 0.06–0.08) for antigenic sites and 0.022 [0.020–0.024]
or all HA sites. Pairwise distances from the corresponding vac-
ine strain were lower for A(H3N2) isolates (0.023 [0.023–0.038]
or antigenic sites and 0.018 [0.014–0.021] for all HA sites). Amino
cid distances between vaccine and circulating A(H1N1)pdm09 and
(H3N2) viruses tended to be lower for common haplotypes than
or singleton haplotypes (Figs. 2b and 4b). For A(H3N2), median
mino acid distances from vaccine strains at antigenic sites were
igniﬁcantly higher for the most recent clade 3C.2 viruses than for
he predominant 3C.3 clade viruses (median 0.034 [0.030–0.038]
s. 0.026 [0.023–0.038]; P = 0.0423 by Kruskal–Wallis test). By
ocation, median pairwise amino acid distances at antigenic sites
etween A(H3N2) and the vaccine strain were signiﬁcantly lower
or viruses collected from Valencia than for those collected from St.
etersburg (0.023 [0.023–0.030] vs. 0.038 [0.023–0.038]; P = 0.0003
y Kruskal–Wallis test).
Patients were considered vaccinated for inﬂuenza if the vaccine
ad been administered ≥14 days before the onset of symptoms. In
t. Petersburg, none of the patients had been vaccinated. In Valen-
ia, 23% (8/34) of patients with A(H1N1)pdm09 infection and 46%
12/26) with A(H3N2) infection had received the corresponding
eason’s inﬂuenza vaccine. Most vaccinated individuals (7/8) car-
ied either the A(H1N1) antigenic haplotype aHap1 or the A(H3N2)
ntigenic haplotype aHap6, both also common in unvaccinated
ndividuals. The relationship between genetic characteristics of the
iral isolates and patient age or vaccination status could not be
ssessed because of insufﬁcient sample sizes.b) for inﬂuenza A(H3N2). Sites are numbered according the previously published
 the reference sequence. Abbreviations: N, number of viruses collected; pw/dist,
total number of patients in the group; VLC, Valencia. *Pairwise amino acid distances
implemented in MEGA6.
5. Discussion
The current analysis revealed some local genetic differences in
inﬂuenza A viruses from Valencia and St. Petersburg. The most fre-
quent haplotypes (combinations of amino acid substitutions) at
antigenic sites were common at both locations. However, analysis
of the entire HA gene region revealed population-speciﬁc haplo-
types across the full length of HA, suggesting that variation across
geographical regions may  be shared within but not outside of
antigenic epitopes. We  deduced that intra-seasonal haplotypes co-
circulated and did not displace one another during the 2013/14
epidemic season, and that the greatest amino acid sequence diver-
sity occurred during the peak of inﬂuenza activity.
Nucleotide variation was  lower at antigenic sites of
A(H1N1)pdm09 viruses than in other HA regions, suggesting
antigenic stability. Conversely, in A(H3N2) viruses, nucleotide
variation was highest at HA antigenic sites. As expected, irrespec-
tive of the viral subtype, nucleotide variation was 10-fold lower at
non-synonymous than at synonymous sites. These ﬁndings are in
line with the known high rates of adaptive evolution in the HA1
domain and structurally mediated purifying selection at other
sites in inﬂuenza HA genes [22]. The antigenically relevant amino
acids varied more in inﬂuenza A(H3N2) isolates than H1N1pdm09
isolates, probably reﬂecting greater immunological pressure due
to longer circulation and vaccine exposure.
We found a clear temporal pattern with co-circulation of phylo-
genetic groups and subgroups. For A(H3N2) viruses, we  identiﬁed
94% of the isolates clustering with the previous season’s dominant
clade 3C.3. In contrast, for A(H1N1)pdm09, all isolates clustered
with clade 6B, which was  newly dominant in 2013/14. These results
agree with ﬁndings in Canada [20]. We  also report here the emer-
gence of clade 3C.2 in A(H3N2) viruses at both study sites. Pairwise
amino acid distances between antigenic sites of A(H3N2) circulat-
ing and vaccine viruses were greater for viruses belonging to this
most recent clade 3C.2 than for viruses belonging to the predomi-
nant 3C.3 clade, suggesting that antigenic drift was already ongoing
towards the end of the 2013/14 season.
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Our study has some limitations that preclude exploring the dif-
erential variability of inﬂuenza viruses between the two study sites
n full. Most importantly, sample size, especially for the Russian
nﬂuenza A virus isolates, was too small to capture the full extent
f viral genetic diversity, precluding reliable statements. Also, viral
hylogenies were based only on the HA gene and were constructed
rom relatively few sequences.
Identifying inﬂuenza vaccine strains that will be antigenically
atched with circulating strains the next season remains a chal-
enge [9]. HA inhibition-based antigenic distances are currently
sed as a proxy for vaccine-virus relatedness [23] but their utility
or predicting vaccine protection is limited [9]. Pairwise genetic dis-
ances between vaccine and circulating strains have been proposed
s a proxy for antigenic similarity between vaccine and circulat-
ng viruses [24,25], but we are still a long way from correlating
nﬂuenza HA genetic changes with vaccine performance, and sero-
ogic investigations (hemagglutination inhibition or neutralization
ests) are needed to complement the genetic data. However, gen-
rating and reporting viral genetic data following a systematic
pproach will allow for additional sensitive and speciﬁc measure-
ents to complement current epidemiological and functional data
20,26], to better correlate vaccine efﬁcacy with speciﬁc muta-
ion patterns in circulating inﬂuenza viruses [9,27], and ultimately
mprove selection of candidate vaccine strains.
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